Cell and gene therapies often promise unparalleled treatment options for patients, but sometimes those benefits come at an extraordinary cost. The therapy class is responsible for the world’s most expensive drugs, including the recently FDA-approved gene therapy, Libmeldy, with a wholesale acquisition cost of $4.25 million. The prior record holder, Hemgenix, had a $3.5 million…
Big Pharma, it’s time to talk: Investors demand transparency on patent thickets
Pharmaceutical companies are running into pushback for their “patent thicket” tactics, designed to maintain exclusive rights and delay cheaper generics. The Financial Times reported that an ethical investor coalition is pushing for greater transparency and urging major drug makers to disclose their patent strategies. Unraveling the patent thicket mystery Patent thickets are a common intellectual property…